These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33244248)

  • 41. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
    Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
    [No Abstract]   [Full Text] [Related]  

  • 42. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function.
    Zhou S; Zhang Y; Wang T; Huang S; Gong S; Wang J; Yu P
    Diabetes Metab; 2021 Sep; 47(5):101274. PubMed ID: 34481963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.
    Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N
    J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.
    Cha AS; Chen Y; Fazioli K; Rivara MB; Devine EB
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1225-1234. PubMed ID: 33248440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study.
    Horii T; Oikawa Y; Kunisada N; Shimada A; Atsuda K
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33246930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
    Packer M; Butler J; Filippatos G; Zannad F; Ferreira JP; Zeller C; Brueckmann M; Jamal W; Pocock SJ; Anker SD;
    Eur J Heart Fail; 2020 Dec; 22(12):2393-2398. PubMed ID: 33251659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
    Yang AY; Chen HC
    Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
    Sawamura T; Karashima S; Nagase S; Nambo H; Shimizu E; Higashitani T; Aono D; Ohbatake A; Kometani M; Demura M; Furukawa K; Takeda Y; Yoneda T
    BMC Endocr Disord; 2020 Nov; 20(1):177. PubMed ID: 33256676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
    Konkwo C; Perry RJ
    Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
    Boorsma EM; Beusekamp JC; Ter Maaten JM; Figarska SM; Danser AHJ; van Veldhuisen DJ; van der Meer P; Heerspink HJL; Damman K; Voors AA
    Eur J Heart Fail; 2021 Jan; 23(1):68-78. PubMed ID: 33251643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A; Nakamura A; Cho KY; Kawata S; Nomoto H; Nagai S; Sugawara H; Taneda S; Tsuchida K; Omori K; Yokoyama H; Takeuchi J; Aoki S; Kurihara Y; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HYPERCALCEMIC PATIENT DIAGNOSED WITH PRIMARY HYPERPARATHYROIDISM AFTER DAPAGLIFLOZIN TREATMENT.
    Akhanlı P; Hepsen S; Ucan B; Saylam G; Cakal E
    AACE Clin Case Rep; 2020; 6(6):e319-e321. PubMed ID: 33244493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.
    Farah SJ; Masri N; Ghanem H; Azar M
    AACE Clin Case Rep; 2020; 6(6):e349-e351. PubMed ID: 33244501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
    Bamgboye AO; Oni IO; Collier A
    Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knockdown of SGLT1 prevents the apoptosis of cardiomyocytes induced by glucose fluctuation via relieving oxidative stress and mitochondrial dysfunction.
    Chai Q; Miao J; Liu M; Zhang Z; Meng Z; Wu W
    Biochem Cell Biol; 2021 Jun; 99(3):356-363. PubMed ID: 33259229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and Risk Factors for Acute Postoperative Pain After Elective Orthopedic and General Surgery at a Tertiary Referral Hospital in Tanzania.
    Ndebea AS; van den Heuvel SAS; Temu R; Kaino MM; van Boekel RLM; Steegers MAH
    J Pain Res; 2020; 13():3005-3011. PubMed ID: 33244259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.